|
1
|
Rizvi NA, Hellmann MD, Snyder A, Kvistborg
P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al: Cancer
immunology. Mutational landscape determines sensitivity to PD-1
blockade in non-small cell lung cancer. Science. 348:124–128. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lortet-Tieulent J, Soerjomataram I, Ferlay
J, Rutherford M, Weiderpass E and Bray F: International trends in
lung cancer incidence by histological subtype: adenocarcinoma
stabilizing in men but still increasing in women. Lung Cancer.
84:13–22. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Markou A, Sourvinou I, Vorkas PA, Yousef
GM and Lianidou E: Clinical evaluation of microRNA expression
profiling in non small cell lung cancer. Lung Cancer. 81:388–396.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yang JJ, Chen HJ, Yan HH, Zhang XC, Zhou
Q, Su J, Wang Z, Xu CR, Huang YS, Wang BC, et al: Clinical modes of
EGFR tyrosine kinase inhibitor failure and subsequent management in
advanced non-small cell lung cancer. Lung Cancer. 79:33–39. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus docetaxel in advanced
squamous-cell non-small-cell lung cancer. N Engl J Med.
373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Herbst RS, Baas P, Kim DW, Felip E,
Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al:
Pembrolizumab versus docetaxel for previously treated,
PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):
a randomised controlled trial. Lancet. 387:1540–1550. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó
L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, et al:
Crizotinib versus chemotherapy in advanced ALK-positive lung
cancer. N Engl J Med. 368:2385–2394. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Molina R, Filella X, Augé JM, Fuentes R,
Bover I, Rifa J, Moreno V, Canals E, Viñolas N, Marquez A, et al:
Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients
with non-small cell lung cancer as an aid in histological diagnosis
and prognosis. Comparison with the main clinical and pathological
prognostic factors. Tumour Biol. 24:209–218. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Okamura K, Takayama K, Izumi M, Harada T,
Furuyama K and Nakanishi Y: Diagnostic value of CEA and CYFRA 21-1
tumor markers in primary lung cancer. Lung Cancer. 80:45–49. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Köttgen A, Albrecht E, Teumer A, Vitart V,
Krumsiek J, Hundertmark C, Pistis G, Ruggiero D, O'Seaghdha CM,
Haller T, et al LifeLines Cohort Study; CARDIoGRAM Consortium;
DIAGRAM Consortium; ICBP Consortium; MAGIC Consortium, :
Genome-wide association analyses identify 18 new loci associated
with serum urate concentrations. Nat Genet. 45:145–154. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen P, Zhao X and Ma L: Downregulation of
microRNA-100 correlates with tumor progression and poor prognosis
in hepatocellular carcinoma. Mol Cell Biochem. 383:49–58. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xu C, Zeng Q, Xu W, Jiao L, Chen Y, Zhang
Z, Wu C, Jin T, Pan A, Wei R, et al: miRNA-100 inhibits human
bladder urothelial carcinogenesis by directly targeting mTOR. Mol
Cancer Ther. 12:207–219. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ashworth A, Rodrigues G, Boldt G and Palma
D: Is there an oligometastatic state in non-small cell lung cancer?
A systematic review of the literature. Lung Cancer. 82:197–203.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fu HL, Wu DP, Wang XF, Wang JG, Jiao F,
Song LL, Xie H, Wen XY, Shan HS, Du YX, et al: Altered miRNA
expression is associated with differentiation, invasion, and
metastasis of esophageal squamous cell carcinoma (ESCC) in patients
from Huaian, China. Cell Biochem Biophys. 67:657–668. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang XD, Xu XH, Zhang SY, Wu Y, Xing CG,
Ru G, Xu HT and Cao JP: Role of miR-100 in the radioresistance of
colorectal cancer cells. Am J Cancer Res. 5:545–559.
2015.PubMed/NCBI
|
|
17
|
Qin C, Huang RY and Wang ZX: Potential
role of miR-100 in cancer diagnosis, prognosis, and therapy. Tumour
Biol. 36:1403–1409. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gong Y, He T, Yang L, Yang G, Chen Y and
Zhang X: The role of miR-100 in regulating apoptosis of breast
cancer cells. Sci Rep. 5:116502015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huang JS, Egger ME, Grizzle WE and McNally
LR: MicroRNA-100 regulates IGF1-receptor expression in metastatic
pancreatic cancer cells. Biotech Histochem. 88:397–402. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Leite KR, Morais DR, Reis ST, Viana N,
Moura C, Florez MG, Silva IA, Dip N and Srougi M: MicroRNA 100: a
context dependent miRNA in prostate cancer. Clinics (São Paulo).
68:797–802. 2013. View Article : Google Scholar
|
|
21
|
Chen J, Zheng B, Wang C, Chen Y, Du C,
Zhao G, Zhou Y and Shi Y: Prognostic role of microRNA-100 in
various carcinomas: evidence from six studies. Tumour Biol.
35:3067–3071. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cao YH, Zhang HH, Xu HF, Duan YJ, Li Q and
Huang B: Prognostic role of microRNA-100 in patients with bladder
cancer. Genet Mol Res. 14:15948–15954. 2015. View Article : Google Scholar : PubMed/NCBI
|
